J 2020

Administration of the Probiotic Escherichia coli Strain A0 34/86 Resulted in a Stable Colonization of the Human Intestine During the First Year of Life

MICENKOVÁ, Lenka, Juraj BOSÁK, Stanislav SMATANA, Adam NOVOTNÝ, Eva BUDINSKÁ et. al.

Basic information

Original name

Administration of the Probiotic Escherichia coli Strain A0 34/86 Resulted in a Stable Colonization of the Human Intestine During the First Year of Life

Authors

MICENKOVÁ, Lenka (703 Slovakia, belonging to the institution), Juraj BOSÁK (703 Slovakia, belonging to the institution), Stanislav SMATANA (703 Slovakia, belonging to the institution), Adam NOVOTNÝ (203 Czech Republic, belonging to the institution), Eva BUDINSKÁ (703 Slovakia, belonging to the institution) and David ŠMAJS (203 Czech Republic, guarantor, belonging to the institution)

Edition

Probiotics and Antimicrobial Proteins, New York, Springer New York LLC, 2020, 1867-1306

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

10606 Microbiology

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

Impact factor

Impact factor: 4.609

RIV identification code

RIV/00216224:14110/20:00114097

Organization unit

Faculty of Medicine

UT WoS

000541342000003

Keywords in English

Colinfant; E. coli; Enterobacteriaceae; Probiotic; Sequencing

Tags

International impact, Reviewed
Změněno: 17/8/2020 10:26, Mgr. Tereza Miškechová

Abstract

V originále

Colinfant New Born (CNB) is an orally administered probiotic preparation containing theEscherichia colistrain A0 34/86, which is specially marketed for use in newborns and infants. Although the impact of different probiotics on the composition of the human gut microbiota has been previously described, the effects ofE. coliprobiotic consumption during infancy on the development of intestinal microbiota are not known. The effect of oral administration of CNB on theEnterobacteriaceaepopulation was mapped using 16S rRNA gene sequencing in DNA samples isolated from the stools of one infant collected at 177 different time points during the first year of life.E. colistrains turnover was analyzed based on the detection of 26 genetic determinants, phylogroups, and pulsed-field gel electrophoresis (PFGE) analysis. Administration of CNB during the second and third month of life introduced theEscherichiagenus to the infant's intestinal tract, andEscherichiabecame dominant among theEnterobacteriaceaefamily (p < 0.01). Genetic determinants, typical for probioticE. coliA0 34/86 strain, were detected on the first day after application of CNB and persisted all year. In addition, nine transientE. colistrains were identified; these strains harbored different genetic determinants and showed different PFGE profiles. Transient strains were detected from 2 to 24 days in the stool samples. The firstEscherichiacolonizer originated from the application of the CNB probiotic preparation. ProbioticE. coliA0 34/86 successfully colonized the intestinal tract of an infant and became resident during the first year of life.

Links

EF15_003/0000469, research and development project
Name: Cetocoen Plus
EF16_013/0001761, research and development project
Name: RECETOX RI
GA16-21649S, research and development project
Name: Molekulární charakterizace nových bakteriocinů identifikovaných v rodech Escherichia a Shigella
Investor: Czech Science Foundation
GJ17-24592Y, research and development project
Name: Mapování interakcí mezi základními metabolickými pochody a střevní mikroflórou
Investor: Czech Science Foundation
LM2015051, research and development project
Name: Centrum pro výzkum toxických látek v prostředí (Acronym: RECETOX RI)
Investor: Ministry of Education, Youth and Sports of the CR
LM2015085, research and development project
Name: CERIT Scientific Cloud (Acronym: CERIT-SC)
Investor: Ministry of Education, Youth and Sports of the CR, CERIT Scientific Cloud
MUNI/M/1322/2015, interní kód MU
Name: Analysis of gastrointestinal microbiome in patients with primary immune deficiencies
Investor: Masaryk University, INTERDISCIPLINARY - Interdisciplinary research projects